Literature DB >> 25784985

Functional characterization of OPN in human laryngeal squamous cell carcinoma and its xenograft model in nude mice.

Jianqiu Chen1, Qi Zhou2, Chunsheng Zhu1, Minhui Zhu3, Yongsheng Tian4, Guojun Li5, Xiaofeng Tao6, Hongliang Zheng3.   

Abstract

BACKGROUND: Osteopontin (OPN) is involved in promotion of cancer cells by regulating various facets of tumor progression such as cell proliferation, angiogenesis and metastasis. To understand the role of OPN in laryngeal squamous cell carcinoma (LSCC), we thus explored the biological function of OPN in LSCC after silencing OPN expression by RNA interference (RNAi).
METHOD: The OPN expression in tumor tissues of LSCC was determined immunohistochemically in both LSCC and adjacent normal tissues. Lentivirus vector with RNAi small hairpin gene sequence of OPN (named LV-shOPN) was transfected into Hep-2 cells and transplanted into BALB/c-nu mice. After siRNA transfection, the viability of Hep-2 cells was examined by MTS, OPN expression was detected by Western blotting, and tumor angiogenesis was assessed by microvessel densities (MVD).
RESULTS: The difference of positive rate of OPN in 72 cases LSCC (54 cases, 75.0%) and adjacent normal tissues (15 cases, 20.8%) was statistically significant (P<0.001) and the OPN expression was also significantly correlated with tumor stage, grade and the presence of lymph node. Hep-2 cells infected with LV-shOPN significantly decreased OPN expression, in comparison to cells with LV-shNon transfection (as the control) (P<0.05). The constructed LV-shOPN effectively inhibited the viability of Hep-2 cell and growth of xenograft tumors in nude mice (all P<0.050). The expression of OPN and MVD was significantly decreased in xenograft tumors (all P<0.05).
CONCLUSION: RNAi silencing of OPN expression can significantly inhibit tumor growth and angiogenesis of Hep-2 cells, and OPN may be considered as one of gene targeting therapy for LSCC.

Entities:  

Keywords:  Osteopontin; RNA interference; laryngeal neoplasms; laryngeal squamous cell carcinoma; nude mice

Year:  2015        PMID: 25784985      PMCID: PMC4358440     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  33 in total

1.  A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen.

Authors:  Karen Meerovitch; Frédéric Bergeron; Lorraine Leblond; Brigitte Grouix; Cathy Poirier; Monica Bubenik; Laval Chan; Henriette Gourdeau; Terry Bowlin; Giorgio Attardo
Journal:  Vascul Pharmacol       Date:  2003-02       Impact factor: 5.773

Review 2.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

3.  World Health Organization classification of tumours: pathology and genetics of head and neck tumours.

Authors:  Lester Thompson
Journal:  Ear Nose Throat J       Date:  2006-02       Impact factor: 1.697

4.  Clinical significance of elevated osteopontin levels in head and neck cancer patients.

Authors:  Mayumi Eto; Satoru Kodama; Nozomi Nomi; Naoki Uemura; Masashi Suzuki
Journal:  Auris Nasus Larynx       Date:  2007-01-24       Impact factor: 1.863

5.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

6.  Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.

Authors:  Yutaka Shimada; Go Watanabe; Junichiro Kawamura; Toshiya Soma; Michio Okabe; Tetsuo Ito; Harutaka Inoue; Masato Kondo; Yukiko Mori; Eiji Tanaka; Masayuki Imamura
Journal:  Oncology       Date:  2005-07-07       Impact factor: 2.935

7.  Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.

Authors:  Matthias Bache; Rolf Reddemann; Harun M Said; Hans-Jürgen Holzhausen; Helge Taubert; Axel Becker; Thomas Kuhnt; Gabriele Hänsgen; Jürgen Dunst; Dirk Vordermark
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-10-23       Impact factor: 7.038

Review 8.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

Review 9.  Cancer of the larynx.

Authors:  Lisa Licitra; Jacques Bernier; Cesare Grandi; Laura Locati; Marco Merlano; Gemma Gatta; Jean-Louis Lefebvre
Journal:  Crit Rev Oncol Hematol       Date:  2003-07       Impact factor: 6.312

10.  Receptor-ligand interaction between CD44 and osteopontin (Eta-1).

Authors:  G F Weber; S Ashkar; M J Glimcher; H Cantor
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.